Cargando…

SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics

Human leukocyte antigen (HLA) molecules play a crucial role in directing adaptive immune responses based on the nature of their peptide ligands, collectively coined the immunopeptidome. As such, the study of HLA molecules has been of major interest in the development of cancer immunotherapies such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim Kam Sian, Terry C. C., Goncalves, Gabriel, Steele, Joel R., Shamekhi, Tima, Bramberger, Liesl, Jin, Dongbin, Shahbazy, Mohammad, Purcell, Anthony W., Ramarathinam, Sri, Stoychev, Stoyan, Faridi, Pouya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272402/
https://www.ncbi.nlm.nih.gov/pubmed/37334365
http://dx.doi.org/10.3389/fimmu.2023.1107576
_version_ 1785059485984751616
author Lim Kam Sian, Terry C. C.
Goncalves, Gabriel
Steele, Joel R.
Shamekhi, Tima
Bramberger, Liesl
Jin, Dongbin
Shahbazy, Mohammad
Purcell, Anthony W.
Ramarathinam, Sri
Stoychev, Stoyan
Faridi, Pouya
author_facet Lim Kam Sian, Terry C. C.
Goncalves, Gabriel
Steele, Joel R.
Shamekhi, Tima
Bramberger, Liesl
Jin, Dongbin
Shahbazy, Mohammad
Purcell, Anthony W.
Ramarathinam, Sri
Stoychev, Stoyan
Faridi, Pouya
author_sort Lim Kam Sian, Terry C. C.
collection PubMed
description Human leukocyte antigen (HLA) molecules play a crucial role in directing adaptive immune responses based on the nature of their peptide ligands, collectively coined the immunopeptidome. As such, the study of HLA molecules has been of major interest in the development of cancer immunotherapies such as vaccines and T-cell therapies. Hence, a comprehensive understanding and profiling of the immunopeptidome is required to foster the growth of these personalised solutions. We herein describe SAPrIm, an Immunopeptidomics tool for the Mid-Throughput era. This is a semi-automated workflow involving the KingFisher platform to isolate immunopeptidomes using anti-HLA antibodies coupled to a hyper-porous magnetic protein A microbead, a variable window data independent acquisition (DIA) method and the ability to run up to 12 samples in parallel. Using this workflow, we were able to concordantly identify and quantify ~400 - 13000 unique peptides from 5e5 - 5e7 cells, respectively. Overall, we propose that the application of this workflow will be crucial for the future of immunopeptidome profiling, especially for mid-size cohorts and comparative immunopeptidomics studies.
format Online
Article
Text
id pubmed-10272402
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102724022023-06-17 SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics Lim Kam Sian, Terry C. C. Goncalves, Gabriel Steele, Joel R. Shamekhi, Tima Bramberger, Liesl Jin, Dongbin Shahbazy, Mohammad Purcell, Anthony W. Ramarathinam, Sri Stoychev, Stoyan Faridi, Pouya Front Immunol Immunology Human leukocyte antigen (HLA) molecules play a crucial role in directing adaptive immune responses based on the nature of their peptide ligands, collectively coined the immunopeptidome. As such, the study of HLA molecules has been of major interest in the development of cancer immunotherapies such as vaccines and T-cell therapies. Hence, a comprehensive understanding and profiling of the immunopeptidome is required to foster the growth of these personalised solutions. We herein describe SAPrIm, an Immunopeptidomics tool for the Mid-Throughput era. This is a semi-automated workflow involving the KingFisher platform to isolate immunopeptidomes using anti-HLA antibodies coupled to a hyper-porous magnetic protein A microbead, a variable window data independent acquisition (DIA) method and the ability to run up to 12 samples in parallel. Using this workflow, we were able to concordantly identify and quantify ~400 - 13000 unique peptides from 5e5 - 5e7 cells, respectively. Overall, we propose that the application of this workflow will be crucial for the future of immunopeptidome profiling, especially for mid-size cohorts and comparative immunopeptidomics studies. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272402/ /pubmed/37334365 http://dx.doi.org/10.3389/fimmu.2023.1107576 Text en Copyright © 2023 Lim Kam Sian, Goncalves, Steele, Shamekhi, Bramberger, Jin, Shahbazy, Purcell, Ramarathinam, Stoychev and Faridi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lim Kam Sian, Terry C. C.
Goncalves, Gabriel
Steele, Joel R.
Shamekhi, Tima
Bramberger, Liesl
Jin, Dongbin
Shahbazy, Mohammad
Purcell, Anthony W.
Ramarathinam, Sri
Stoychev, Stoyan
Faridi, Pouya
SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
title SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
title_full SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
title_fullStr SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
title_full_unstemmed SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
title_short SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
title_sort saprim, a semi-automated protocol for mid-throughput immunopeptidomics
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272402/
https://www.ncbi.nlm.nih.gov/pubmed/37334365
http://dx.doi.org/10.3389/fimmu.2023.1107576
work_keys_str_mv AT limkamsianterrycc saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT goncalvesgabriel saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT steelejoelr saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT shamekhitima saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT brambergerliesl saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT jindongbin saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT shahbazymohammad saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT purcellanthonyw saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT ramarathinamsri saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT stoychevstoyan saprimasemiautomatedprotocolformidthroughputimmunopeptidomics
AT faridipouya saprimasemiautomatedprotocolformidthroughputimmunopeptidomics